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Introduction: The goal of this study was to investigate (1) the associations of rheumatoid arthritis (RA)-related
inflammation or rheumatoid factor/anti-cyclic citrullinated peptide (anti-CCP) positivity with lipid profiles and insulin
resistance (IR), (2) the effects of biologic therapy on lipid profiles and IR, and (3) potential predictors for the
presence of subclinical atherosclerosis.
Methods: Serum levels of lipid profiles were determined by enzymatic methods in 32 adalimumab-treated patients,
16 etanercept-treated patients, 24 tocilizumab-treated patients, and 20 biologic-naïve patients. Atherogenic index,
which corresponds to the ratio of total cholesterol to high-density lipoprotein cholesterol (HDL-C), was calculated. IR
was measured by homeostasis model assessment. Pro-inflammatory cytokine levels were examined by enzyme-linked
immunosorbent assay. Common carotid artery intima-media thickness was determined by using sonography.
Results: There was an inverse correlation between disease activity (disease activity score for 28 joints, or DAS28)
and low-density lipoprotein cholesterol (LDL-C) levels (r = −0.226, P <0.05) and a positive correlation between
DAS28 and IR (r = 0.361, P <0.005). Anti-CCP-positive patients had significantly higher DAS28 and IR compared with
anti-CCP-negative patients. There was also a positive correlation between IR and levels of interleukin-6 or tumor
necrosis factor-alpha (TNF-α). HDL-C levels significantly increased in patients receiving 6-month anti-TNF-α therapy,
and levels of total cholesterol, LDL-C, and triglyceride increased in tocilizumab-treated patients. IR significantly
decreased in patients under biologic therapy but was unchanged in biologic-naïve patients. Age, IR, and DAS28
were significant predictors of severe subclinical atherosclerosis (odds ratios of 1.08, 2.77, and 2.52, respectively).
Conclusions: Significant associations of RA-related inflammation with lipid profiles and IR indicate the involvement
of RA in atherosclerosis pathogenesis. Biologic therapies were associated with IR reduction without change in
atherogenic index, but their beneficial effects on atherosclerosis reduction need to be verified in the future.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
articular disease [1,2] that is complicated by accelerated
atherosclerosis and subsequently leads to adverse cardio-
vascular (CV) events [3,4]. Epidemiological studies have
disclosed an increased risk of premature atherosclerosis* Correspondence: dychen@vghtc.gov.tw
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stated.and an increased mortality due to CV events in patients
with RA [5-7].
Atherosclerosis-associated CV diseases (CVDs) are at-
tributable to the traditional risk factors, including hyper-
tension, dyslipidemia, diabetes mellitus (DM), and smoking
in the general population [8,9]. A recent meta-analysis of
traditional risk factors for CVD in patients with RA indi-
cated an important role of low levels of high-density lipo-
protein cholesterol (HDL-C) and an increased frequency of
DM [10]. A nationwide cohort study demonstrates that
RA is associated with the same risk of myocardial in-
farction as DM [11].
RA-related inflammation that is responsible for syn-
ovial lesions may be implicated in the development ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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CVD [12,13]. Furthermore, the magnitude and chronicity
of inflammation strongly correlated with the emergence of
premature atherosclerosis in RA [3,6,12,14]. The positivity
of rheumatoid factor (RF) or anti-cyclic citrullinated pep-
tide (anti-CCP) antibodies or both appears to be associ-
ated with high prevalence of subclinical atherosclerosis in
RA [15]. In addition, the presence of HLA-DRB1*04
shared epitope alleles and tumor necrosis factor (TNF)
A-308 (rs1800629) gene polymorphism is associated
with a higher risk of CVD in patients with RA [16,17].
Recent clinical studies identified elevated levels of pro-
inflammatory cytokines, including TNF-α and interleukin-6
(IL-6), as independent variables in association with arthro-
sclerosis in rheumatic patients and the general population
[13,14,18]. TNF-α causes deterioration of the lipid profile
and promotes insulin resistance (IR), both of which are
traditional risk factors for atheroscerlosis [14,18]. There-
fore, TNF-α inhibitors can induce favorable changes in
lipid profiles with alteration of HDL composition [19]. Al-
though previous studies failed to show that anti-TNF-α
therapy could lower the risk of CVD [20,21], accumulating
evidence suggests that TNF-α inhibitors can reduce the
risk of future CV events in RA [22]. Besides the improve-
ment of endothelial function [23], the possible mecha-
nisms include a decrease of RA-associated inflammation,
improvement of lipid profile [19], and the reduction of IR
[24]. IL-6, a pro-inflammatory cytokine, may play a central
role in decreasing total cholesterol (TC) levels and may
also contribute to an increased IR in RA [25,26]. Toci-
lizumab, a humanized monoclonal antibody against IL-6
receptor (IL-6R), is effective in the treatment of RA
[27,28]. Tocilizumab induced elevation of low-density
lipoprotein cholesterol (LDL-C) but altered HDL parti-
cles toward an anti-inflammatory composition in RA
[29]. These observations indicate that the reduction of RA-
related inflammation and modulation of atherosclerosis-
associated cytokines could be a potential strategy for the
prevention of atherosclerosis in patients with RA.
Ultrasonography (US) of the carotid artery provides a
non-invasive method for identifying atherosclerotic pla-
ques, which reflect severe subclinical atherosclerosis and
may predict the emergence of adverse CV events [30-33].
Common carotid artery intima-media thickness (ccIMT)
measurements were shown to reflect the extent of coron-
ary atherosclerosis [30,31]. Previous studies also showed
that an increased ccIMT and evidence of plaques could
predict the emergence of CVD in patients with RA [31,32].
Therefore, increased ccIMT or carotid plaques or both
could be used as the gold standard for identification of
severe subclinical atherosclerosis and patients at high
risk of CVD [31-33].
The main objectives of this study were (1) to evaluate
the associations of RA-related inflammation or RF/anti-CCP positivity with serum levels of lipid profile, athero-
genic index (AI), modified Framingham CV risk score
(mFRS), IR, and pro-inflammatory cytokines; (2) to in-
vestigate the effects of biologic therapy on serum levels
of lipid profiles, AI, mFRS, and IR in patients with RA;
and (3) to examine the potential predictive factors and




In total, 92 consecutive biologic-naïve patients who ful-
filled the 2010 revised criteria of the American College of
Rheumatology for RA [34] were enrolled. Each of them
had received traditional synthetic disease-modifying anti-
rheumatic drugs (tsDMARDs), including methotrexate
(MTX). Seventy-two patients started anti-TNF-α or
anti-IL-6R therapy in combination with a stable dose of
MTX 7.5 to 15 mg weekly in accordance with the guide-
lines of the British Society for Rheumatology [35], whereas
the other 20 patients continued with MTX therapy and
other tsDMARDs (as the disease control). Patients with a
recent history (within 1 year) of coronary heart disease or
cerebral ischemic stroke were excluded from this study.
Thirty-two patients received adalimumab at a dose of
40 mg every other week, 16 patients received etanercept
at a dose of 25 mg twice weekly, and 24 patients received
tocilizumab at a dose of 4 mg/kg once monthly during the
first 3 months and then 8 mg/kg once monthly afterward,
with concomitant MTX at a stable dose of 7.5 to 15 mg
weekly. The doses of tsDMARDs as well as oral cortico-
steroids remained unchanged and the use of intra-
articular or parenteral corticosteroids was prohibited
during the period of investigation. Disease activity was
assessed by the 28-joint disease activity score (DAS28)
at baseline and after 6 months of biologic or tsDMARD-
alone therapy, respectively [36]. The therapeutic re-
sponse was evaluated after 6 months of therapy by using
the European League Against Rheumatism (EULAR) re-
sponse criteria [37]. We defined EULAR responders as
patients with good and moderate EULAR therapeutic
responses. The Institutional Review Board of Taichung
Veterans General Hospital approved this study (CE12274),
and the written consent of all participants was obtained in
accordance with the Declaration of Helsinki.
Measurements of serum levels of lipid profiles and
atherogenic index
All measurements were performed after an overnight
fasting of 12 hours at baseline and after 6 months of bio-
logic or tsDMARD-alone therapy, respectively. Serum
levels of TC, triglyceride (TG), HDL-C, and LDL-C
were measured by using enzymatic methods by a chem-
istry analyzer (Hitachi 7600; Hitachi, Tokyo, Japan) in
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The AI, which corresponds to the ratio of TC to HDL-C,
was calculated.
Measurements of the Framingham risk score and modified
Framingham risk score
FRS was determined on the basis of the demographic
data and traditional risk factors [38]. The FRS estimates
the 10-year risk of adverse CV events, including heart
attack, stroke, or other occlusive arterial disease. Consid-
ering additional risks for patients with RA, we adopt a
modified FRS (mFRS) by the application of a multiplier
factor of 1.5 to those with two of the following three
criteria: disease duration of more than 10 years, RF or
anti-CCP antibody positivity, and the presence of extra-
articular manifestations [39].
Measurements of insulin resistance
Serum insulin levels were determined by using a commer-
cially available assay kit (IMMULITE, I-2000; EURO/
Diagnostic Products Cooperation, Gwynedd, UK). Homeo-
stasis model assessment for IR (HOMA-IR) was calculated
by using this formula: fasting plasma insulin (in micro-
international units per liter) × fasting plasma glucose (in
millimoles per liter)/22.5 [40].
Ultrasound vascular imaging of carotid artery
Ultrasound vascular imaging for carotid arteries in-
cluded measurement of ccIMT and detection of focal
plaques in the extracranial carotid tree. The final ccIMT
was represented by the largest average ccIMT measured
at the far wall of the common carotid arteries along a
10-mm section of the artery proximal to the carotid bi-
furcation, and the proximal 15-mm-long segment of
the internal and external carotid arteries. Plaque was
defined as a localized thickening of more than 1.5 mm
that did not uniformly involve the whole artery accord-
ing to Mannheim consensus criteria [41]. A ccIMT of
more than 0.90 mm or carotid plaques (or both) is de-
fined as the gold standard for severe subclinical athero-
sclerosis [42].
Determination of serum levels of pro-inflammatory cytokines
Serum levels of TNF-α and IL-6 were determined in 32
adalimumab-treated patients, 16 etanercept-treated pa-
tients, 14 tocilizumab-treated patients, and 10 biologic-
naïve patients by using an enzyme-linked immunosorbent
assay (PeproTech Inc., Rocky Hill, NJ, USA) in accordance
with the instructions of the manufacturer.
Statistical analysis
Results are presented as the mean ± standard deviation
(SD) or standard error of mean (SEM). The non-
parametric Kruskal-Wallis test was used for comparisonsbetween groups. When this test showed a significant dif-
ference, the exact P value was determined by using the
Mann-Whitney U test. The independent samples t test
was used for between-group (positivity and negativity for
RF/anti-CCP antibodies) comparison of baseline levels of
lipid profiles, AI, mFRS, IR, and pro-inflammatory cyto-
kines. The non-parametric Spearman’s correlations were
determined between RA disease activity (DAS28) and
levels of lipid profiles, AI, mFRS, IR, or pro-inflammatory
cytokines. For comparison of levels of lipid profiles, AI,
mFRS, IR, and pro-inflammatory cytokines during follow-
up in RA patients before and after biologic therapy, the
Wilcoxon signed rank test was employed. We also con-
structed a logistic regression model to evaluate the con-
tribution of traditional risk factors and RA-related risk
factors to the presence of severe subclinical atheroscler-
osis detected by US. The optimal cutoff values of age,
AI, mFRS, IR, and DAS28 for the occurrence of severe
subclinical atherosclerosis was determined by using
receiver operating characteristic (ROC) curve analysis.
The diagnostic sensitivity and specificity were deter-
mined by using MedCalc statistical software version 9.3
(MedCalc Software, Ostend, Belgium). A probability of
less than 0.05 was considered significant.Results
Clinical characteristics of patients with rheumatoid
arthritis
As illustrated in Table 1, the majority of patients with
RA were women and all patients had active disease
(DAS28 of more than 3.2) at baseline. Among these
patients, 78.3% were positive for RF and 69.6% were
positive for anti-CCP antibodies; 58 (63.0%) had a dis-
ease duration of at least 10 years; 13 (14.1%) patients
had extra-articular manifestations, including secondary
Sjögren’s syndrome in eight patients, interstitial lung
disease in four, pleuritis/pericarditis in two, rheumatoid
nodule in one, and rheumatoid vasculitis in one). Accord-
ing to the results of carotid US, 57.1% of patients with RA
had severe subclinical atherosclerosis. There were no sig-
nificant differences in the positive rate of RF/anti-CCP
antibodies, daily dose of corticosteroids, weekly dose of
MTX, or proportion of tsDMARDs used among four sub-
groups of RA patients at baseline.
After 6 months of biologic or tsDMARD-alone ther-
apy, 25 (78.1%) adalimumab-treated patients, 13 (81.3%)
etanercept-treated patients, and 20 (83.3%) tocilizumab-
treated patients were EULAR responders. However, only
50% of biologics-naïve patients were EULAR responders.
The mean DAS28 changes (± SDs) were 2.00 ± 0.88 in
adalimumab-treated patients, 1.86 ± 0.92 in etanercept-
treated patients, and 2.13 ± 0.99 in tocilizumab-treated
patients, while a significantly lower change in DAS28
Table 1 Demographic data and laboratory findings at baseline in four subgroups of rheumatoid arthritis patients
according to therapeutic agents used
Adalimumab (n = 32) Etanercept (n = 16) Tocilizumab (n = 24) Without biologic (n = 20)
Mean age, years 53.5 ± 12.6 54.4 ± 7.8 56.8 ± 14.4 57.0 ± 11.4
Female proportion 28 (87.5%) 13 (81.3%) 20 (83.3%) 17 (85.0%)
Disease duration, years 13.4 ± 6.6 13.6 ± 9.0 13.0 ± 9.7 12.3 ± 5.8
Body mass index, kg/m2 24.8 ± 4.6 23.6 ± 4.5 24.5 ± 3.7 22.9 ± 2.9
RF positivity 28 (87.5%) 13 (81.3%) 17 (70.8%) 14 (70.0%)
Anti-CCP positivity 21 (65.6%) 11 (68.8%) 17 (70.8%) 15 (75.0%)
Baseline ESR, mm/1st hour 33.5 ± 23.4 39.0 ± 36.0 42.5 ± 30.0 35.8 ± 22.1
Baseline DAS28 5.46 ± 0.94 5.48 ± 0.98 5.80 ± 0.85 5.12 ± 0.59
Daily steroid dose, mg/day 6.3 ± 2.5 6.9 ± 1.9 7.4 ± 2.1 7.0 ± 2.2
DMARDs at baseline
MTX, weekly dose, mg 12.0 ± 2.5 10.6 ± 3.7 11.5 ± 2.5 11.3 ± 2.8
Sulfasalazine 27 (84.4%) 12 (75.0%) 18 (75.0%) 17 (85.0%)
Hydroxychloroquine 24 (75.0%) 12 (75.0%) 19 (79.2%) 18 (90.0%)
Cyclosporine 6 (18.7%) 4 (25.0%) 5 (20.8%) 7 (35.0%)
Hypertension 14 (43.8%) 6 (37.5%) 8 (33.3%) 8 (40.0%)
Antihypertensive Rx 8 (25.0%) 4 (25.0%) 7 (29.2%) 6 (30.0%)
Diabetes mellitus 2 (6.2%) 1 (6.3%) 1 (4.2%) 1 (5.0%)
Hypoglycemic Rx 1 (3.1%) 1 (6.3%) 0 (0.0%) 0 (0.0%)
Current smoker 3 (9.4%) 2 (16.6%) 3 (12.5%) 3 (15.0%)
Data are presented as mean ± standard deviation or as number (percentage). anti-CCP, anti-cyclic citrullinated peptide (antibodies); DAS28, disease activity
score for 28 joints; DMARDs, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RF, rheumatoid factor;
Rx, treatment.
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(P <0.001, P <0.01, and P <0.001, respectively).Associations of rheumatoid factor/anti-CCP antibody
positivity with lipid profiles, atherogenic index,
modified Framingham risk score, insulin resistance, and
pro-inflammatory cytokines at baseline
Compared with patients with negative RF, those with
positive RF had significantly higher baseline DAS28
(mean ± SEM, 5.63 ± 0.11 versus 5.13 ± 0.17, P <0.01), IR
(2.85 ± 0.22 versus 1.95 ± 0.28, P <0.05), TNF-α levels
(285.61 ± 87.78 pg/mL versus 48.19 ± 8.03 pg/mL, P <0.05),
and IL-6 levels (734.16 ± 245.38 pg/mL versus 230.28 ±
54.94 pg/mL, P <0.01) (Figure 1A-C). Similarly, anti-
CCP-positive patients had significantly higher values in
these parameters compared with anti-CCP-negative pa-
tients: baseline DAS28 (5.69 ± 0.11 versus 5.00 ± 0.13,
P <0.01), IR (3.02 ± 0.22 versus 1.58 ± 0.19, P <0.01), TNF-
α levels (289.74 ± 89.45 pg/mL versus 49.58 ± 8.23 pg/mL,
P <0.05), and IL-6 levels (748.48 ± 250.21 versus 220.63 ±
45.34, P <0.01) (Figure 1D-F). However, there were no
significant differences in serum levels of lipid profile,
AI, or mFRS between seropositive patients and sero-
negative patients.Association of rheumatoid arthritis DAS28 with lipid
profiles, atherogenic index, modified Framingham risk
score, insulin resistance, DAS28, and pro-inflammatory
cytokines at baseline
As shown in Figure 2, there was an inverse correlation be-
tween DAS28 and LDL-C levels and a positive correlation
between DAS28 and IR, anti-CCP level, or levels of cyto-
kines, including TNF-α and IL-6. However, there was no
significant correlation between DAS28 and AI or mFRS.
Correlation between cytokine levels and lipid profiles,
atherogenic index, modified Framingham risk score, or
insulin resistance at baseline
There was an inverse correlation between IL-6 levels and
LDL-C levels (r = −0.269, P <0.05) and a positive correlation
between IL-6 levels and IR (r = 0.326, P <0.01). There was a
positive correlation between TNF-α levels and IR (r = 0.416,
P <0.005). However, there was no significant correlation be-
tween cytokine levels and lipid profiles or mFRS.
Change in lipid profiles, atherogenic index, modified
Framingham risk score, and insulin resistance after
therapy with or without biologics
Serum HDL-C levels significantly increased (mean ± SEM,
71.29 ± 2.24 mg/dL versus 75.40 ± 2.88 mg/mL, P <0.05)
Figure 1 The associations of RF/anti-CCP antibody positivity with lipid profiles. (A) Comparisons of serum levels of lipid profile between RA
patients with positive rheumatoid factor (RF) [RF(+)] and negative RF [RF(−)]. (B) Comparisons of baseline DAS28, atherogenic index (AI), modified
Framingham CV risk scores (mFRS), insulin resistance between RA patients with positive RF and negative RF. (C) Comparisons of proinflammatory
cytokines between RA patients with positive RF and negative RF. (D) Comparisons of serum levels of lipid profile between RA patients with positive
anti-CCP antibodies [anti-CCP (+)] and negative anti-CCP antibodies [anti-CCP (−)]. (E) Comparisons of baseline DAS28, atherogenic index (AI), modified
Framingham CV risk scores (mFRS), insulin resistance between RA patients with positive anti-CCP antibodies and negative anti-CCP antibodies.
(F) Comparisons of proinflammatory cytokines between RA patients with positive anti-CCP antibodies and negative anti-CCP antibodies.
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shown in Figure 3 and Table 2, there was no significant
change in serum levels of lipid profiles, AI, or mFRS in pa-
tients receiving 6 months of adalimumab or etanercept.Among tocilizumab-treated patients, levels of TC, LDL-C,
and TG significantly increased without significant changes
in HDL-C levels or AI. It is interesting that IR significantly
decreased after 6 months of biologic therapy, including
Figure 2 (See legend on next page.)
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Figure 2 The association of disease activity (DAS28) with lipid profiles, AI, mFRS, IR, and proinflammatory cytokines. (A) The correlation
between DAS28 and serum levels of total cholesterol. (B) The correlation between DAS28 and serum levels of HDL-C. (C) The correlation between
DAS28 and serum levels of low-density LDL-C. (D) The correlation between DAS28 and serum levels of TG. (E) The correlation between DAS28 and
atherogenic index (AI). (F) The correlation between DAS28 and modified Framingham CV risk scores (FRS). (G) The correlation between DAS28 and
insulin resistance (IR). (H) The correlation between DAS28 and anti-CCP levels. (I) The correlation between DAS28 and serum levels of TNF-α. (J) The
correlation between DAS28 and serum levels of IL-6.
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was no significant change in levels of lipid profile, AI,
mFRS, or IR in those not treated with biologic therapy.
Logistic regression analysis
As illustrated in Table 3, univariate regression analysis
demonstrated that age, AI, mFRS, IR, disease duration of
more than 10 years, and DAS28 were identified as poten-
tial predictors of severe subclinical atherosclerosis (odds
ratio, 1.09, P <0.001; 2.12, P <0.05; 1.20, P <0.05; 2.43,
P <0.001; 3.33, P <0.01; and 2.94, P <0.005, respectively).
To establish the best model to predict subclinical athero-
sclerosis, multivariate regression analysis was performed
by choosing the variables that were significant by uni-
variate regression analysis. Age, IR, and DAS28 were
demonstrated as significant predictors of severe subclinical
atherosclerosis (odds ratio, 1.08, P <0.01; 2.77, P <0.005;
and 2.52, P <0.05; respectively).
Determination of the optimal cutoff values of predictive
variables by receiver operating characteristic analysis
The optimal cutoff value of age for predicting the occur-
rence of severe subclinical atherosclerosis was 59 years
(area under ROC curve [AUC] of 0.784, sensitivity of
63.5%, and specificity of 84.6%, P <0.001), the optimal cut-
off value of AI was 3.02 (AUC of 0.654, sensitivity of
55.8%, and specificity of 71.8%, P <0.01), the optimal cutoff
value of mFRS was 2.0 (AUC of 0.701, sensitivity of 59.6%,
and specificity of 76.9%, P <0.001), the optimal cutoff
value of IR was 1.27 (AUC of 0.791, sensitivity of 94.2%,
and specificity of 53.9%, P <0.001), and the optimal cutoff
value of DAS28 was 5.28 (AUC of 0.741, sensitivity of
67.3%, and specificity of 76.9%, P <0.001).
Discussion
In the present study, we demonstrated an inverse correl-
ation between RA-related inflammation (DAS28) and
serum LDL-C levels and a positive correlation between
DAS28 and IR as well as levels of cytokines, including
TNF-α and IL-6, at baseline. Moreover, patients who were
seropositive for RF or anti-CCP antibodies had signifi-
cantly higher DAS28, IR, TNF-α levels, and IL-6 levels
compared with seronegative patients. After 6 months of
biologic therapy, serum HDL-C levels significantly in-
creased in patients receiving anti-TNF-α therapy, and
levels of TC, LDL-C, and TG significantly increased intocilizumab-treated patients. IR significantly decreased
after 6 months of therapy with TNF-α inhibitors or IL-
6R inhibitor, but AI did not show significant change.
There was no significant change in levels of lipid
profiles, AI, mFRS, or IR in patients who did not receive
biologic therapy. In addition, multivariate regression
analysis revealed that age, IR, and DAS28 were potential
predictors of severe subclinical atherosclerosis.
Dyslipidemia is a well-established traditional risk fac-
tor for atherosclerosis [4,9,10,43]. Although the differ-
ences in the lipid profile between RA patients and the
general population remain to be clarified, RA-related in-
flammation may be responsible for the change in lipid
profiles [13-15,44]. Recent studies demonstrated that
female patients with RA had significantly lower LDL-C
levels than women in the general population [45,46].
Consistent with the findings of a previous study [44],
our results showed an inverse correlation between RA-
related inflammation (DAS28) and LDL-C levels in pa-
tients with RA. The lower LDL-C levels, in conjunction
with elevated risk of CVDs in RA patients compared
with the general population [5-7,46], support the hypoth-
esis of a lipid paradox in this disease [44]. When compared
with seronegative patients for RF or anti-CCP antibodies,
our seropositive patients had significantly higher IR, con-
sistent with a recent report that seropositivity is associated
with IR in patients with inflammatory polyarthritis [47]. In
agreement with a previous study that the presence of anti-
CCP antibodies appears to be associated with a high
prevalence of subclinical atherosclerosis in RA [15], we
demonstrated that patients with anti-CCP positivity had
higher IR and DAS28, which have been implicated in the
occurrence of atherosclerosis.
Accumulating evidence indicates that the accelerated
atherosclerosis in RA cannot be explained by traditional
risk factors alone [44]. Our results showed a positive
correlation between RA disease activity (DAS28) and IR,
which is an independent risk factor for atherosclerotic
CVD [48]; these findings suggest that RA-related inflam-
mation, as reflected by DAS28, is important in the emer-
gence of IR. Our data also were consistent with the
findings that patients with high-grade inflammation were
more likely to have a high IR than those with low-grade
inflammation [49]. In addition, pro-inflammatory cyto-
kines, including TNF-α and IL-6, which are involved in
RA pathogenesis, play a critical role in atherosclerosis in
Figure 3 (See legend on next page.)
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Figure 3 Change in lipid profiles, AI, mFRS, and IR after therapy with or without biologics. (A1) The changes in serum levels of lipid profile after
6 months of therapy in adalimumab-treated patients. (A2) The changes in AI, mFRS, and IR after 6 months of therapy in adalimumab-treated
patients. (B1) The changes in serum levels of lipid profile after 6 months of therapy in etanercept-treated patients. (B2) The changes in AI,
mFRS, and IR after 6 months of therapy in etanercept-treated patients. (C1) The changes in serum levels of lipid profile after 6 months of
therapy in tocilizumab-treated patients. (C2) The changes in AI, mFRS, and IR after 6 months of therapy in tocilizumab-treated patients.
(D1) The changes in serum levels of lipid profile after 6 months treatment in biologic-naïve patients. (D2) The changes in AI, mFRS, and IR after
6 months treatment in biologic-naïve patients.
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onstrated that levels of TNF-α and IL-6 were positively
correlated with both DAS28 and IR in patients with RA.
Our results were consistent with those of previous stud-
ies showing that TNF-α promotes IR [14,18] and that
IL-6 may contribute to an elevated IR [25,26]. Further-
more, our observations support the conclusion that RA-
related inflammation and pro-inflammatory cytokines
play an increasingly important role in the pathogenesis
of IR in patients with RA [50].
During a longitudinal follow-up of patients with RA,
we found that HDL-C levels were significantly increased
in patients receiving 6 months of anti-TNF-α therapy,
consistent with the results of previous studies [19,51,52].
In agreement with a systemic review with meta-analysis
[53], our study showed no significant changes in LDL-CTable 2 Change in lipid profiles, AI, mFRS, and IR in patients
Adalimumab (n = 32) Etanercept
Total cholesterol, mg/dL
Baseline 212.3 ± 5.8 195.3 ± 9.8
Week 24 212.1 ± 5.6 191.0 ± 7.9
HDL-C, mg/dL
Baseline 73.0 ± 2.7 67.5 ± 4.1
Week 24 77.1 ± 3.8 71.7 ± 4.0
LDL-C, mg/dL
Baseline 131.3 ± 5.3 118.4 ± 8.9
Week 24 127.0 ± 5.6 117.0 ± 7.4
Triglyceride, mg/dL
Baseline 105.6 ± 8.3 129.8 ± 21.1
Week 24 105.7 ± 7.1 106.4 ± 12.0
Atherogenic index
Baseline 3.00 ± 0.11 3.05 ± 0.29
Week 24 2.91 ± 0.14 2.75 ± 0.16
Modified FRS
Baseline 3.52 ± 0.65 4.22 ± 1.44
Week 24 3.42 ± 0.72 4.22 ± 1.40
Insulin resistance
Baseline 2.75 ± 0.29 2.90 ± 0.53
Week 24 1.76 ± 0.39* 1.71 ± 0.26**
Data are presented as mean ± standard error of mean. *P <0.05, **P <0.005, versus
risk score; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoproteilevels or AI in patients receiving 6 months of anti-TNF-α
therapy. The findings of increases in levels of TC, LDL-C,
and TG without apparent change in AI in our patients
under anti-IL-6R therapies were consistent with previous
reports [28,29,54,55]. These observations suggest that AI
is less susceptible to the fluctuation of disease activity,
making it more appropriate for predicting CVD risk in RA
patients than individual lipid levels. Whether the changes
in lipid profiles after biologic therapy contribute to CVD
risk remains unclear.
It is interesting that there was a significant decrease in
IR in patients receiving 6 months of anti-TNF-α therapy
but that there was no significant change in IR in those
receiving biologic-naïve therapies. Our results were similar
to the findings of a study showing that knockout mice
lacking TNF-α expression demonstrated improved IR [56],receiving biologic or biologic-naïve therapy
(n = 16) Tocilizumab (n = 24) Without biologic (n = 20)
191.8 ± 5.3 209.6 ± 11.2
211.5 ± 6.8* 199.5 ± 8.6
67.7 ± 3.3 70.4 ± 4.4
72.1 ± 4.0 70.8 ± 5.2
119.2 ± 5.5 123.4 ± 9.1
134.3 ± 6.5* 114.2 ± 6.0
118.8 ± 9.8 86.9 ± 9.3
135.5 ± 11.4* 88.9 ± 9.6
2.94 ± 0.12 3.11 ± 0.18
3.11 ± 0.16 3.01 ± 0.20
3.48 ± 0.91 3.43 ± 0.93
4.04 ± 0.97* 3.25 ± 0.79
2.97 ± 0.38 2.28 ± 0.34
1.99 ± 0.25** 1.77 ± 0.18
before treatment, determined by Wilcoxon signed rank test. FRS, Framingham
n cholesterol.
Table 3 Univariate and multivariate association of
traditionalcardiovascular risk factors and RA-rated factors
with severe subclinical atherosclerosis
Risk factors (univariate) Odds ratio 95% confidence
interval
P value
Age 1.09 1.04-1.14 0.000
Sex (female) 0.89 0.18-4.39 0.883
Smoking status 3.87 0.79-19.06 0.096
Hypertension Rx. 1.35 0.55-3.32 0.517
Body mass index 0.95 0.86-1.05 0.328
Total cholesterol 1.00 0.98-1.01 0.491
HDL-C 1.01 0.98-1.04 0.467
LDL-C 1.00 0.98-1.01 0.511
Total triglyceride 1.00 0.99-1.02 0.640
Artherogenic index 2.12 1.05-4.25 0.035
Modified FRS 1.20 1.01-1.42 0.033
Insulin resistance 2.43 1.50-3.93 0.000
Disease duration >10 years 3.33 1.36-8.15 0.008
RF positivity 1.41 0.44-4.44 0.562
Anti-CCP positivity 1.44 0.89-2.35 0.142
TNF-α levels 1.00 0.99-1.00 0.743
IL-6 levels 1.00 1.00-1.00 0.196
DAS28 2.94 1.58-5.49 0.001
Risk factors (multivariate) Odds ratio 95% confidence
interval
P value
Age 1.08 1.02-1.15 0.007
Artherogenic index 1.31 0.98-1.76 0.073
Modified FRS 1.17 0.97-1.40 0.093
Insulin resistance 2.77 1.40-5.46 0.003
Disease duration >10 years 5.89 0.93-37.16 0.059
DAS28 2.52 1.00-6.35 0.049
Anti-CCP, anti-cyclic citrullinated peptide (antibodies); DAS28, disease activity
score for 28-joints; FRS, Framingham risk score; HDL-C, high-density lipoprotein
cholesterol; IL-6, interleukin-6; LDL-C, low-density lipoprotein cholesterol;
RF, rheumatoid factor; Rx, treatment; TNF-α, tumor necrosis factor-alpha.
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beneficial effects of anti-TNF-α therapy on IR [24,52].
However, Rosenvinge et al. reported no significant change
in IR from baseline in nine RA patients after 2 months of
adalimumab therapy [57]. The discrepancy may be caused
by the small number of subjects and a short-term therapy
that was not long enough to detect treatment-related
changes in IR. Similarly, we demonstrated a significant de-
crease in IR in patients receiving 6 months of anti-IL-6R
(tocilizumab) therapy. Our results were consistent with
a recent study that tocilizumab therapy decreases IR in
patients with RA [58]. These observations imply that
biologic therapies that block TNF-α or IL-6 reduce IR,
which is critical in the development of atherosclerosis
in patients with RA.To identify potential predictors for the occurrence of
severe subclinical atherosclerosis [42], a logistic regres-
sion analysis was performed. Univariate analysis demon-
strated that age, AI, mFRS, IR, disease duration of more
than 10 years, and DAS28 were significant predictors of
severe subclinical atherosclerosis. Our results supported
previous studies revealing that age, AI, and FRS at base-
line were associated with the occurrence of subclinical
atherosclerosis in patients with RA [59,60]. Our data
were also similar to another study reporting that IR was
an individual predictor for identifying subjects with ca-
rotid plaque [61]. Disease duration of more than 10 years
was a significant predictor of subclinical atherosclerosis
in this study resonated with previous findings that a
higher ccIMT was observed in RA patients with longer
disease duration [62], and supported the claim that RA
patients with disease duration of more than 10 years
would need to undergo carotid US [63]. DAS28 was also
a significant predictor of subclinical atherosclerosis,
consistent with the findings of previous studies showing
that RA-related inflammation is implicated in the devel-
opment of atherosclerosis [12,13]. Similar to the results
of other studies [15,64], we demonstrated a trend of an
association of anti-CCP positivity with the occurrence
of subclinical atherosclerosis (p=0.142). However, our
findings should be verified by further extensive studies
because of the use of a large number of variates in this
small sample of patients.
Selection of the optimal cutoff value of age, AI, mFRS,
IR, and DAS28 at baseline for predicting severe subclin-
ical atherosclerosis may have clinical implications. Using
ROC analysis, we demonstrated that patients with age
above 59 years, AI above 3.02, mFRS above 2.0, IR above
1.27, and DAS28 above 5.28 might have a high probability
of developing severe subclinical atherosclerosis. However,
our results are preliminary; hence, the use of these cutoff
values in clinical practice cannot be recommended until
their external validity has been confirmed.
Some limitations in this study should be addressed. This
is a preliminary study that enrolled a limited number of
active RA patients who were followed up for 6 months.
Actual CV events and mortality were not available, and
positive results of carotid US were used as a surrogate
marker of severe subclinical atherosclerosis. In consid-
eration of the effects of corticosteroids and multiple
DMARDs on levels of lipid profile, we did not analyze
the differences in baseline levels of lipid profiles be-
tween RA patients and healthy subjects. However, re-
cent studies and a meta-analysis have demonstrated the
differences in lipid profiles between RA patients and a
healthy population [10,45,46]. In addition, none of the
enrolled patents in our study was in an early stage of
RA and this may limit the generalizability of these results
to the whole population. A long-term study enrolling
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lation, who receive biologic therapy and tsDMARDs alone
is required to confirm these data. Because adipokines are
of main relevance in the development of the metabolic
syndrome frequently observed in patients with RA, the
investigation of the effects of biologic therapy on adipo-
kines [65] would be needed. Finally, qualitative changes
in lipid profile such as HDL-C subfractions [66] and
small dense LDL-C particles were not addressed.Conclusions
Our results show significant associations of RA-related
inflammation with LDL-C levels and IR. Patients with
seropositive RA had significantly higher DAS28, IR, and
levels of pro-inflammatory cytokines at baseline when
compared with seronegative patients. Biologic therapies
are associated with a significant increase in HDL-C
levels (TNF-α inhibitors) or levels of TC, LDL-C, and
TG (IL-6R inhibitor) without apparent change in AI.
Biologic therapies could also improve insulin sensitivity.
Age, AI, mFRS, IR, long disease duration, and DAS28
could predict the emergence of subclinical atherosclerosis
in patients with RA. Early identification of traditional risk
factors, tight control of RA-related inflammation with
biological therapy, and ongoing monitoring of CVD risk
factors are mandatory for slowing the progression of
atherosclerosis in patients with RA.
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